[Funding alert] Edinburgh-based PhaSER Biomedical Secures $2.3Million in Funding

Tuesday 20, 2024 | By Startup Rise EU

Edinburgh-based PhaSER Biomedical secures $2.3million in funding to continue its pioneering work in accelerating drug discovery and development from the Bill & Melinda Gates Foundation.

Edinburgh-based PhaSER Biomedical secures $2.3million in funding to continue its pioneering work in accelerating drug discovery and development from the Bill & Melinda Gates Foundation.

PhaSER will provide 8HUM transgenic mouse models, humanised for key pathways involved in the metabolism and disposition of drugs, to all the foundation grantees.

Read also - London-based Kynd Secures an Undisclosed Amount Funding

These models recapitulate the ways drugs are metabolised in humans and have multiple applications in drug discovery and development: including drug efficacy, the prediction of drug/drug interactions and the more informed design of clinical trials.

8HUM models will accelerate the discovery and development of new treatments of disease, reduce attrition when drugs reach the clinic as well as reduce animal use and development costs.

Read also - Oxford-based MeVitae Raises €1.7 Million in Seed Funding

The three-year programme will make the PhaSER technology a collaborating institution within the Global Health Discovery Collaboratory Programme, which is funded by the Gates Foundation.

This will provide collaborating researchers who are involved in combatting diseases such as Malaria, TB, HIV, pandemic preparedness, and non-hormonal contraception with access to this powerful drug discovery and development platform.

Read also - UK-based Codestone Acquired Cloud Business

Professor Roland Wolf, PhaSER’s Founder, commented: “We are delighted to receive this support from the Gates Foundation, which will allow us to provide these valuable mice to drug discovery groups working on some of the most pressing global health care challenges we are faced with today. We look forward to continuing our work to accelerate and improve drug discovery activities.”

About PhaSER Biomedical

PhaSER Biomedical was formed in 2022 from 8HUM technology developed by Taconic Farms, CXR Biosciences and the University of Dundee over a 20 year period. PhaSER is now collaborating with multiple companies, universities and charitable organisations to ensure the ground-breaking 8HUM mouse model is used as widely as possible in global drug discovery and development applications.

Read also - Berlin-based Monite Secures $6Million in Seed Funding

Recommended Stories for You

story
News

Switzerland-based 14Peaks Secures €28 million its First Fund

Startup Rise EU Tuesday 23, 2024

story
News

German-based Octomind Secures $4.8 Million in Seed Funding

Startup Rise EU Tuesday 23, 2024

story
News

Dublin-based SynOx Therapeutics Secures $75Million in Series B Round Funding

Startup Rise EU Tuesday 23, 2024

story
News

Paris-based Zefir Secures €11Million in Funding

Startup Rise EU Tuesday 23, 2024

story
News

Helsinki-based HappySignals Secures €12 Million in Funding

Startup Rise EU Tuesday 23, 2024

story
News

Italian-based Lithium Lasers Secures €2 Million in Funding

Startup Rise EU Monday 22, 2024